Mar 13
Nektar outlines $400M–$460M year-end 2026 cash target as REZPEG enters Phase III in atopic dermatitis
Synthesized from 1 source
Sources (1)
Bias Scale:
LeftCenterRight
Seeking AlphaMar 13, 2026, 7:22 AM
Nektar outlines $400M–$460M year-end 2026 cash target as REZPEG enters Phase III in atopic dermatitis88High Trust
Comments
No comments yet. Be the first!